EFMC-ASMC'19
Conferences > Upcoming events > EFMC-ASMC'19

Confirmed Speakers


Opening Lecture

Opening Lecture
The Art and Science of Total Synthesis and its Impact on Biology and Medicine: From the Fundamentals to the Translational (T01)
Prof. K.C. NICOLAOUProf. K.C. NICOLAOU
(RICE UNIVERSITY, Houston, United States)

Read more

Invited Speakers

Flow Chemistry and Photochemistry as a Tool for Drug Discovery (T23)
Dr Jesus ALCAZARDr Jesus ALCAZAR
(JANSSEN RESEARCH & DEVELOPMENT, Toledo, Spain)

Read more
Awareness of PAINS (Pan Assay Interference Compounds) can Accelerate the Drug Discovery Process (T14)
Prof. Jonathan BAELLProf. Jonathan BAELL
(MONASH UNIVERSITY, Parkville, Australia)

Read more
Artificial Intelligence in ADMET Modeling and Compound Profiling (T15)
Dr Karl-Heinz BARINGHAUSDr Karl-Heinz BARINGHAUS
(SANOFI, Frankfurt, Germany)

Read more
TLR7/8 Antagonists: from Screening to in vivo Potency (T26)
Dr Claudia BETSCHARTDr Claudia BETSCHART
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Read more
RNA Therapeutics: New Chemical Modalities Becoming a Therapeutic Reality (T25)
Dr Konrad BLEICHERDr Konrad BLEICHER
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Read more
Sustainable by Design Anti-Trypanosomatid Small Molecules: an Aspirational Goal for Medicinal Chemistry (T16) - ChemMedChem Lecture
Prof. Maria Laura BOLOGNESIProf. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

Read more
Catalytic Chirality Generation: New Strategies for Organic Synthesis (T06)
Prof. John BOWERProf. John BOWER
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom)

Read more
Nature’s Medicine Chest: Opportunities for Synthesis and Drug Discovery (T02)
Prof. Margaret Anne BRIMBLEProf. Margaret Anne BRIMBLE
(THE UNIVERSITY OF AUCKLAND, Auckland, New Zealand)

Read more
Allosteric Activation of a Master Metabolic Regulator AMPK: Drug Discovery Opportunities and Challenges (T27)
Dr Kimberly CAMERONDr Kimberly CAMERON
(PFIZER, Cambridge, United States)

Read more
Design and Synthesis of Chemical Probes for Bromodomains (T10)
Prof. Stuart CONWAYProf. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
Start Selective and Rigidify: The Discovery Path Towards the Next Generation of EGFR Tyrosine Kinase Inhibitors (T24)
Dr Harald ENGELHARDTDr Harald ENGELHARDT
(BOEHRINGER-INGELHEIM, Vienna, Austria)

Read more
Artificial Intelligence in de Novo Molecular Design (T17)
Dr Ola ENGKVISTDr Ola ENGKVIST
(ASTRAZENECA, Mölndal, Sweden)

Read more
Design and Implementation of de Novo Biosynthetic Cascades (T20)
Prof. Sabine FLITSCHProf. Sabine FLITSCH
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

Read more
Catalysis for Total Synthesis (T21)
Prof. Alois FÜRSTNERProf. Alois FÜRSTNER
(MAX PLANCK INSTITUT FUR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

Read more
Amides and Chemical Education as Vehicles for Innovation (T18)
Prof. Neil GARGProf. Neil GARG
(UNIVERSITY OF CALIFORNIA, Los Angeles, United States)

Read more
A Chemical Approach to Map Protein Interactions at the Cell Surface (T12)
Dr Erik HETTDr Erik HETT
(MERCK EXPLORATORY SCIENCE CENTER, Boston, United States)

Read more
A Medicinal Chemist's Perspective on Solute Carriers: Avoiding or Targeting them (T11)
Dr Kim HUARDDr Kim HUARD
(GENENTECH, San Francisco, United States)

Read more
Practical Heteroatom- and Group-Transfer Reactions (T09)
Dr Laszlo KURTIDr Laszlo KURTI
(RICE UNIVERSITY, Houston, United States)

Read more
Discovery of AZD5718, a Novel 5-lipoxygenase Activating Protein (FLAP) Inhibitor (T19)
Dr Malin LEMURELLDr Malin LEMURELL
(ASTRAZENECA, Gothenburg, Sweden)

Read more
Photoinduced Assembly of C–N Bonds (T08)
Dr Daniele LEONORIDr Daniele LEONORI
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

Read more
Discovery of First in Class, Orally Bioavailable p300/CBP HAT Domain Inhibitors (T04)
Dr Michael MICHAELIDESDr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)

Read more
Drug Discovery in Academia (T03)
Prof. Oliver PLETTENBURGProf. Oliver PLETTENBURG
(LEIBNIZ UNIVERSITY HANNOVER, Hannover, Germany)

Read more
From Fragments to Antibody Drug Conjugates in Emerging Oncology Targeted Therapies (T13)
Dr Laurent SCHIODr Laurent SCHIO
(SANOFI, Vitry sur Seine, France)

Read more
Nucleophilic Boron for the Synthesis of Functionalized Small Rings (T07)
Prof. Mariola TORTOSAProf. Mariola TORTOSA
(AUTONOMOUS UNIVERSITY OF MADRID, Madrid, Spain)

Read more
Development and Application in Flow of Sustainable Synthetic Methodologies that Use Singlet Oxygen as Green Oxidant and Cascade Reaction Facilitator (T22)
Prof. Georgios VASSILIKOGIANNAKISProf. Georgios VASSILIKOGIANNAKIS
(UNIVERSITY OF CRETE, Heraklion, Greece)

Read more
Novel Bacterial Topoisomerase Inhibitors (NBTI) with Potent Gram-Negative Activity (T05)
Dr Cornelia ZUMBRUNNDr Cornelia ZUMBRUNN
(IDORSIA PHARMACEUTICALS, Allschwil, Switzerland)

Read more

Oral Communications

Rapid Exploration of Synthetically Tractable Chemical Space and Lead Optimization Using a Combination of Reaction-Based Enumeration, Active Learning, and Free Energy Calculations (OC02)
Dr Tatjana BRAUNDr Tatjana BRAUN
(SCHRÖDINGER, Mannheim, Germany)

Read more
Developing a ‘Reverse-Biomimetic’ Synthesis of Arogenate and its Analogues (OC09)
Ms Louise EAGLINGMs Louise EAGLING
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom)

Read more
Macrocyclic Modalities for Modulation of Protein-Protein Interactions (OC06)
Dr Stephanie GUERETDr Stephanie GUERET
(ASTRAZENECA MPI SATELLITE UNIT, Dortmund, Germany)

Read more
EFMC Prize for a Young Medicinal Chemist in Academia
From the Elucidation of the Mechanism of Vitamin E to the Design of Innovative Drugs that Limit Inflammation and Enhance Resolution (OC10)
Dr Andreas KOEBERLEDr Andreas KOEBERLE
(UNIVERSITY OF JENA, Jena, Germany)

Read more
Stabilizing Inactive Conformations of MALT1 AS an Effective Strategy to Inhibit its Protease Activity (OC05)
Dr Jean-Baptiste LANGLOISDr Jean-Baptiste LANGLOIS
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Read more
EFMC Prize Winner EFMC-YMCS 2018
Development of Release-And-Report Kinase Inhibitors as Molecular Tools for Investigating Neurodegenerative Disorders (OC04)
Dr Cassandra LEE FLEMING Dr Cassandra LEE FLEMING
(UNIVERSITY OF GOTHENBURG, Gothenburg, Sweden)

Read more
A Radical Approach for the Late-Stage Functionalization of Phosphinic Peptides (OC03)
Mr Angelos LELISMr Angelos LELIS
(UNIVERSITY OF ATHENS, Athens, Greece)
Practical and Asymmetric Gilman-Speeter Synthesis of B-Lactams (OC01)
Prof. Plato MAGRIOTISProf. Plato MAGRIOTIS
(UNIVERSITY OF PATRAS, Patras, Greece)

Read more
Discovery of GSK701, a Novel Orally Effective Preclinical Drug Candidate for the Treatment of Malaria (OC08)
Dr Jose Ignacio MARTINDr Jose Ignacio MARTIN
(GSK, Tres Cantos, Spain)

Read more
Removable Directing Groups for Late-Stage Functionalisation (OC12)
Dr Miriam O'DUILLDr Miriam O'DUILL
(NATIONAL UNIVERSITY OF IRELAND, Galway, Ireland)

Read more
Antimicrobial Activity of Curcumin Analog PGV-6, HGV-6 and GVT-6 (OC07)
Dr Leni RITMALENIDr Leni RITMALENI
(GADJAH MADA UNIVERSITY, Yogyakarta, Indonesia)

Read more
EFMC Prize for a Young Medicinal Chemist in Industry
Cipargamin-Biocatalysis in the Discovery and Development of an Antimalarial Drug (OC11)
Dr Radka SNAJDROVADr Radka SNAJDROVA
(NOVARTIS PHARMA AG, Basel, Switzerland)

Read more

Organised by

Silver Sponsor

Bronze Sponsors

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys